With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.250285-32-6,1,3-Bis(2,6-diisopropylphenyl)imidazolium chloride,as a common compound, the synthetic route is as follows.
General procedure: Under a N2 atmosphere, a mixture of imidazolium salts 1(0.225 mmol), PdCl2 (0.15 mmol), K2CO3 (0.45 mmol) and picolinicacid 2 (0.15 mmol) was stirred in anhydrous THF (2.0 mL) underreux for 12 h. Then the solvent was removed under reducedpressure, and the residue was puried by ash column chroma-tography (SiO2) to give complexes 3 as yellow solids. 4.2.1.1. Compound 3a. yellow solid. m.p. 248C (decomposed).1HNMR (500 MHz, CDCl3, TMS) d 8.55 (d, J 5.5 Hz, 1H), 7.83e7.77 (m,2H), 7.49 (t, J 7.5 Hz, 2H), 7.34 (d, J 7.5 Hz, 4H), 7.31e7.28 (m,1H),7.17 (s, 2H), 2.95 (hept, J 7.0 Hz, 4H), 1.42 (d, J 7.0 Hz, 12H), 1.14(d, J 7.0 Hz, 12H).13C NMR (125 MHz, CDCl3) d 172.7, 157.4, 151.3,146.8, 146.5, 139.1, 134.5, 130.4, 126.6, 126.2, 125.1, 124.0, 28.6, 26.2,22.9. IR (neat) n 2964, 1668, 1600, 1458, 1408, 1337, 1291, 1047, 944,800, 771, 755, 713 cm1. HRMS (ESI) calcd for C33H41ClN3O2Pd[MH]: 654.1920; found: 654.1917. Anal. calcd forC33H40ClN3O2Pd: C, 60.47%; H, 6.18%; N, 6.44%; found: C, 60.62%; H,6.11%; N, 6.31%.
250285-32-6, As the paragraph descriping shows that 250285-32-6 is playing an increasingly important role.
Reference£º
Article; Zhang, Zhi-Mao; Gao, Yu-Jue; Lu, Jian-Mei; Tetrahedron; vol. 73; 52; (2017); p. 7308 – 7314;,
Chiral Catalysts
Chiral catalysts – SlideShare